Abstract
We have used our newly described mouse tissue chamber model [1], to investigate the process of IL-1 production in more detail. The inflammatory reaction in the tissue surrounding the implanted chambers was investigated histologically and by using the polymerase chain reaction (PCR). The inflammatory response included influx of leucocytes into the granuloma surrounding the tissue chamber, expression of IL-1β on macrophages present in the inflamed tissue and an increase in the mRNA coding for IL-1β and IL-6 proteins in the granuloma. The effects of three anti-inflammatory or immunosuppressive drugs, prednisolone, indomethacin and cyclosporin A, on IL-1β and PGE2 production in zymosan andBordetella-pertussis-vaccine (BPV)-challenged tissue chambers were also examined. Oral treatment with prednisolone and cyclosporin A of zymosan-challenged animals showed a dose-dependent reduction of IL-1β concentrations, but no effect of indomethacin. Both prednisolone and indomethacin dose-dependently reduced PGE2 concentrations to control levels, while cyclosporin A was effective only at the highest dose tested (100 mg/kg/day p.o.). In drug-treated BPV-challenged animals, prednisolone and cyclosporin A also showed a dose-dependent reduction of IL-1β, while indomethacin was again ineffective. Prednisolone and indomethacin also dose-dependently reduced the PGE2 concentrations to control levels, whereas cyclosporin A was effective only at the highest dose tested (100 mg/kg/day p.o.).
This model will be useful for investigating the mechanisms controlling the production of IL-1β from the mRNA level to the secretion of mature biologically active protein [1], and in the search for new drugs which could selectively interfere with this process.
Similar content being viewed by others
References
J. Dawson, C. Rordorf, T. Geiger, H. Towbin, S. Kunz, H. Nguyen, O. Zingel, D. Chaplin and K. Vosbeck,Interleukin-1 (IL-1) production in a mouse tissue chamber model of inflammation. I. Development and initial characterisation of the model. Agents and Actions (submitted).
J. M. Chirgwin, A. E. Przybyla, R. J. MacDonald and W. J. Rutter,Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry18, 5294–5299 (1979).
L. J. Murray, R. Lee and C. Martens,In vivo cytokine gene expression in T cell subsets of the autoimmune MRL/Mp-lpr/lpr mouse. Eur. J. Immunol.20, 163–170 (1990).
J. Sambrook, J. Fritsch and T. Maniatis, InMolecular cloning: A Laboratory Manual, Chap. 6, Cold Spring Harbour Press, 1989.
J. B. Smith, M. H. Bocchieri, L. Sherbin-Allen, M. Borofsky and J. L. Abruzzo,Occurrence of interleukin-1 in human synovial fluid: Detection by RIA, bioassay and presence of bioassay-inhibiting factors. Rheumatol. Int.9, 53–58 (1989).
M. E. J. Billingham,Models of arthritis and the search for anti-arthritic drugs, Pharmacol. Ther.21, 389–428 (1983).
M. H. Boer and N. R. Ackerman, The utility of the MRL/1 mouse for detecting anti-arthritic drugs. InHandbook of Animal Models for the Rheumatic Diseases. Vol. 1. (Eds. R. A. Greenwald and H. S. Diamond) pp. 137–146, CRC Press, Florida, 1988.
J. R. Vane,Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature231, 32–39 (1971).
P. Leoni, R. C. Garcia and A. C. Allison,Effects of cyclosporin-A on human lymphocytes in culture. J. Lab. Immunol.1, 67–72 (1978).
J. F. Borel, H. U. Gubler, P. C. Hiestand and R. M. Wenger,Immunological properties of cyclosporin (Sandimmune R)and (Val2) dihydro-cyclosporin and their prospect in chronic inflammation. Adv. Inflam. Res.11, 277–291 (1986).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dawson, J., Rordorf-Adam, C., Geiger, T. et al. Interleukin-1 (IL-1) production in a mouse tissue chamber model of inflammation. II. Identification of (tissue) macrophages as the IL-1 producing cells and the effect of anti-inflammatory drugs. Agents and Actions 38, 255–264 (1993). https://doi.org/10.1007/BF01976218
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01976218